Status of the neonatal screening for CAH and perceived availability of oral fludrocortisone, oral hydrocortisone and injectable hydrocortisone in the WHO Eastern Mediterranean Region and in Algeria
| Countries/territories | CAH NBS | Oral fludrocortisone | Oral hydrocortisone | Injectable hydrocortisone |
| Afghanistan | No information | |||
| Algeria | No | 0% | 100% | 100% |
| Bahrain | No | 75% | 100% | 100% |
| Djibouti | No | 0% | 0% | 75% |
| Egypt | No | 50% | 25% | 75% |
| Iran (Islamic Republic of) | No | 100% | 100% | 100% |
| Iraq | No | 75% | 75% | 75% |
| Jordan | No | 75% | 100% | 100% |
| Kuwait | Yes | 100% | 100% | 100% |
| Lebanon | Yes, only one private hospital | 25% (imported when needed) | 75% | 75% |
| Libya | No | 75% | 75% | 75% |
| Morocco | No | 0% | 75%–100% | 75%–100% |
| Oman | No | 75% | 100% | 100% |
| Pakistan | No | 25% | 100% | 100% |
| Occupied Territory of Palestine | No | 75% | 100% | 100% |
| Qatar | Yes | 100% | 100% | 100% |
| Saudi Arabia | Yes, >50% | 75% | 75% | 100% |
| Somalia | No | 0% | 25% | 100% |
| Sudan | No | 25% | 75% | 75%–100% |
| Syrian Arab Republic | No | 50% | 50% | 100% |
| Tunisia | No | 75% | 75% | 100% |
| United Arab Emirates | Yes | 100% | 100% | 100% |
| Yemen | No | 0% | 0% | 50% |
*Availability of the medicines as estimated by one to four paediatric endocrinologists practicing in the country.
CAH, congenital adrenal hyperplasia; NBS, newborn screening.